Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance

Drug Resistance Updates

Volumn 13, Issue 4-5, 2010, Pages 109-118

  Wang, Zhiwei ^a   Li, Yiwei ^a   Ahmad, Aamir ^a   Azmi, Asfar S ^a   Kong, Dejuan ^a   Banerjee, Sanjeev ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Cancer stem cells; Curcumin.; Drug resistance; EMT; MiRNA; Natural compounds

Indexed keywords

ARSENIC ACID; CARBOPLATIN; CETUXIMAB; CISPLATIN; CURCUMIN; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DOXORUBICIN; EPIGALLOCATECHIN GALLATE; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEFITINIB; GEMCITABINE; IMATINIB; IRINOTECAN; LAPATINIB; METFORMIN; METHOTREXATE; MICRORNA; OXALIPLATIN; PACLITAXEL; SALINOMYCIN; TAMOXIFEN; TEMOZOLOMIDE; TRASTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CANCER STEM CELL; CELL TYPE; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DIABETES MELLITUS; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; LIVER CELL CARCINOMA; LUNG SMALL CELL CANCER; METASTASIS; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; PANCREAS TUMOR; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOPLASTIC STEM CELLS; PLANT PREPARATIONS;

EID: 77957969261     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2010.07.001     Document Type: Article

References (154)

1. Aboody K.S., Najbauer J., Danks M.K. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther. 2008, 15:739-752.
2. Adam L., Zhong M., Choi W., Qi W., Nicoloso M., Arora A., Calin G., Wang H., Siefker-Radtke A., McConkey D., Bar-Eli M., Dinney C. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin. Cancer Res. 2009, 15:5060-5072.
3. Adhikari A.S., Agarwal N., Wood B.M., Porretta C., Ruiz B., Pochampally R.R., Iwakuma T. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res. 2010, 70:4602-4612.
4. Ali S., Ahmad A., Banerjee S., Padhye S., Dominiak K., Schaffert J.M., Wang Z., Philip P.A., Sarkar F.H. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 2010, 70:3606-3617.
5. Arumugam T., Ramachandran V., Fournier K.F., Wang H., Marquis L., Abbruzzese J.L., Gallick G.E., Logsdon C.D., McConkey D.J., Choi W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009, 69:5820-5828.
6. Bandyopadhyay A., Wang L., Agyin J., Tang Y., Lin S., Yeh I.T., De K., Sun L.Z. Doxorubicin in combination with a small TGFβ inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS One 2010, 5:e10365.
7. Bardelli A., Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. 2010, 28:1254-1261.
8. Blick T., Hugo H., Widodo E., Waltham M., Pinto C., Mani S.A., Weinberg R.A., Neve R.M., Lenburg M.E., Thompson E.W. Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J. Mammary Gland Biol. Neoplasia 2010, 15:235-252.
9. Borst P., Jonkers J., Rottenberg S. What makes tumors multidrug resistant?. Cell Cycle 2007, 6:2782-2787.
10. Bourguignon L.Y., Spevak C.C., Wong G., Xia W., Gilad E. Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J. Biol. Chem. 2009, 284:26533-26546.
11. Brabletz T., Jung A., Spaderna S., Hlubek F., Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat. Rev. Cancer 2005, 5:744-749.
12. Bracken C.P., Gregory P.A., Khew-Goodall Y., Goodall G.J. The role of microRNAs in metastasis and epithelial-mesenchymal transition. Cell Mol. Life Sci. 2009, 66:1682-1699.
13. Braun J., Hoang-Vu C., Dralle H., Huttelmaier S. Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene 2010, Epub 24 May 2010. 10.1038/onc.2010.169.
14. Broxterman H.J., Gotink K.J., Verheul H.M. Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist. Updat. 2009, 12:114-126.
15. Broxterman H.J., Lankelma J., Pinedo H.M. How to probe clinical tumour samples for P-glycoprotein and multidrug resistance-associated protein. Eur. J. Cancer 1996, 32A:1024-1033.
16. Cammareri P., Scopelliti A., Todaro M., Eterno V., Francescangeli F., Moyer M.P., Agrusa A., Dieli F., Zeuner A., Stassi G. Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res. 2010, 70:4655-4665.
17. Carey L.A., Dees E.C., Sawyer L., Gatti L., Moore D.T., Collichio F., Ollila D.W., Sartor C.I., Graham M.L., Perou C.M. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 2007, 13:2329-2334.
18. Chen G.Q., Zhao Z.W., Zhou H.Y., Liu Y.J., Yang H.J. Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin. Med. Oncol. 2010, 27:406-415.
19. Cochrane D.R., Spoelstra N.S., Howe E.N., Nordeen S.K., Richer J.K. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol. Cancer Ther. 2009, 8:1055-1066.
20. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009, 10:704-714.
21. Croce C.M., Calin G.A. miRNAs, cancer and stem cell division. Cell 2005, 122:6-7.
22. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
23. DiMeo T.A., Anderson K., Phadke P., Fan C., Perou C.M., Naber S., Kuperwasser C. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res. 2009, 69:5364-5373.
24. Dirks P. Invitation to a second round. Nature 2010, 466:40-41.
25. Dylla S.J., Beviglia L., Park I.K., Chartier C., Raval J., Ngan L., et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008, 3:1-13.
26. Emmink B.L., van Houdt W.J., Vries R.G., Hoogwater F.J., Jimenez C.R., Clevers H., Borel Rinkes I.H., Kranenburg O. Differentiated colorectal cancer cells protect tumor-initiating cells from irinotecan. Proceedings of the American Association of Cancer Research 2010, (Abstract 4294).
27. Fang D.D., Kim Y.J., Lee C.N., Aggarwal S., McKinnon K., Mesmer D., Norton J., Birse C.E., He T., Ruben S.M., Moore P.A. Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery. Br. J. Cancer 2010, 102:1265-1275.
28. Finn R.S., Dering J., Ginther C., Wilson C.A., Glaspy P., Tchekmedyian N., Slamon D.J. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/" triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res. Treat. 2007, 105:319-326.
29. Frank N.Y., Schatton T., Frank M.H. The therapeutic promise of the cancer stem cell concept. J. Clin. Invest. 2010, 120:41-50.
30. Frederick B.A., Helfrich B.A., Coldren C.D., Zheng D., Chan D., Bunn P.A., Raben D. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol. Cancer Ther. 2007, 6:1683-1691.
31. Fuchs B.C., Fujii T., Dorfman J.D., Goodwin J.M., Zhu A.X., Lanuti M., Tanabe K.K. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res. 2008, 68:2391-2399.
32. Fuchs D., Daniel V., Sadeghi M., Opelz G., Naujokat C. Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem. Biophys. Res. Commun. 2010, 394:1098-1104.
33. Fujita Y., Kojima K., Hamada N., Ohhashi R., Akao Y., Nozawa Y., Deguchi T., Ito M. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem. Biophys. Res. Commun. 2008, 377:114-119.
34. Galluzzi L., Morselli E., Vitale I., Kepp O., Senovilla L., Criollo A., et al. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res. 2010, 70:1793-1803.
35. Garofalo M., Di L.G., Romano G., Nuovo G., Suh S.S., Ngankeu A., et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009, 16:498-509.
36. Garofalo M., Quintavalle C., Di L.G., Zanca C., Romano G., Taccioli C., Liu C.G., Croce C.M., Condorelli G. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 2008, 27:3845-3855.
37. Gibbons D.L., Lin W., Creighton C.J., Rizvi Z.H., Gregory P.A., Goodall G.J., Thilaganathan N., Du L., Zhang Y., Pertsemlidis A., Kurie J.M. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev. 2009, 23:2140-2151.
38. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53:615-627.
39. Gregory P.A., Bert A.G., Paterson E.L., Barry S.C., Tsykin A., Farshid G., Vadas M.A., Khew-Goodall Y., Goodall G.J. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 2008, 10:593-601.
40. Gregory P.A., Bracken C.P., Bert A.G., Goodall G.J. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 2008, 7:3112-3118.
41. Gupta P.B., Chaffer C.L., Weinberg R.A. Cancer stem cells: mirage or reality?. Nat. Med. 2009, 15:1010-1012.
42. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., Lander E.S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
43. Gutova M., Najbauer J., Gevorgyan A., Metz M.Z., Weng Y., Shih C.C., Aboody K.S. Identification of uPAR-positive chemoresistant cells in small cell lung cancer. PLoS One 2007, 2:e243.
44. Haagenson K.K., Wu G.S. The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment. Cancer Metastasis Rev. 2010, 29:143-149.
45. Hendrickson A.W., Haluska P. Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy. Curr. Opin. Investig. Drugs 2009, 10:1032-1040.
46. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., Bruns C.J., Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
47. Hirsch H.A., Iliopoulos D., Tsichlis P.N., Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009, 69:7507-7511.
48. Hiscox S., Jiang W.G., Obermeier K., Taylor K., Morgan L., Burmi R., Barrow D., Nicholson R.I. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of β-catenin phosphorylation. Int. J. Cancer 2006, 118:290-301.
49. Hollier B.G., Evans K., Mani S.A. The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J. Mammary Gland Biol. Neoplasia 2009, 14:29-43.
50. Hong S.P., Wen J., Bang S., Park S., Song S.Y. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int. J. Cancer 2009, 125:2323-2331.
51. Hopper-Borge E.A., Nasto R.E., Ratushny V., Weiner L.M., Golemis E.A., Astsaturov I. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin. Ther. Targets. 2009, 13:339-362.
52. Hu L., McArthur C., Jaffe R.B. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br. J. Cancer 2010, 102:1276-1283.
53. Hutvagner G., Simard M.J. Argonaute proteins: key players in RNA silencing. Nat. Rev. Mol. Cell Biol. 2008, 9:22-32.
54. Hutvagner G., Simard M.J., Mello C.C., Zamore P.D. Sequence-specific inhibition of small RNA function. PLoS Biol. 2004, 2:E98.
55. Iorio M.V., Casalini P., Piovan C., Di L.G., Merlo A., Triulzi T., Menard S., Croce C.M., Tagliabue E. microRNA-205 regulates HER3 in human breast cancer. Cancer Res. 2009, 69:2195-2200.
56. Iorio M.V., Croce C.M. MicroRNAs in cancer: small molecules with a huge impact. J. Clin. Oncol. 2009, 27:5848-5856.
57. Ishikawa F., Yoshida S., Saito Y., Hijikata A., Kitamura H., Tanaka S., et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat. Biotechnol. 2007, 25:1315-1321.
58. Ji J., Yamashita T., Budhu A., Forgues M., Jia H.L., Li C., et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 2009, 50:472-480.
59. Ji Q., Hao X., Zhang M., Tang W., Yang M., Li L., et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 2009, 4:e6816.
60. Jiang B.H., Liu L.Z. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist. Updat. 2008, 11:63-76.
61. Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 2006, 12:1167-1174.
62. Kajiyama H., Shibata K., Terauchi M., Yamashita M., Ino K., Nawa A., Kikkawa F. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int. J. Oncol. 2007, 31:277-283.
63. Kakarala M., Brenner D.E., Korkaya H., Cheng C., Tazi K., Ginestier C., Liu S., Dontu G., Wicha M.S. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res. Treat. 2009, 10.1007/s10549-009-0612-x.
64. Kim M.R., Choi H.K., Cho K.B., Kim H.S., Kang K.W. Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells. Cancer Sci. 2009, 100:1834-1841.
65. Kolitz J.E., George S.L., Marcucci G., Vij R., Powell B.L., Allen S.L., et al. P-glycoprotein inhibition using valdospar (PSC-833) does not improve outcomes for patients under age of 60 years with newly diagnosed acute myeloid leukemia: cancer and leukemia group B study 19808. Blood 2010, 10.1182/blood-2009-07-229492.
66. Konecny G.E., Venkatesan N., Yang G., Dering J., Ginther C., Finn R., Rahmeh M., Fejzo M.S., Toft D., Jiang S.W., Slamon D.J., Podratz K.C. Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br. J. Cancer 2008, 98:1076-1084.
67. Kong D., Li Y., Wang Z., Banerjee S., Ahmad A., Kim H.R., Sarkar F.H. miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 2009, 27:1712-1721.
68. Kono S.A., Marshall M.E., Ware K.E., Heasley L.E. The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resist. Updat. 2009, 12:95-102.
69. Konopleva M., Tabe Y., Zeng Z., Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist. Updat. 2009, 12:103-113.
70. Korpal M., Lee E.S., Hu G., Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 2008, 283:14910-14914.
71. Kotani A., Ha D., Hsieh J., Rao P.K., Schotte D., den Boer M.L., Armstrong S.A., Lodish H.F. miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221. Blood 2009, 114:4169-4178.
72. Kovalchuk O., Filkowski J., Meservy J., Ilnytskyy Y., Tryndyak V.P., Chekhun V.F., Pogribny I.P. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol. Cancer Ther. 2008, 7:2152-2159.
73. Lee T.K., Poon R.T., Wo J.Y., Ma S., Guan X.Y., Myers J.N., Altevogt P., Yuen A.P. Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model. Cancer Res. 2007, 67:8800-8809.
74. Lemoli R.M., Salvestrini V., Bianchi E., Bertolini F., Fogli M., Amabile M., et al. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. Blood 2009, 114:5191-5200.
75. Li Y., Kong D., Wang Z., Sarkar F.H. Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm. Res. 2010, 27:1027-1041.
76. Li Y., Li W., Yang Y., Lu Y., He C., Hu G., Liu H., Chen J., He J., Yu H. MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res. 2009, 1286:13-18.
77. Li Y., Vandenboom T.G., Kong D., Wang Z., Ali S., Philip P.A., Sarkar F.H. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009, 69:6704-6712.
78. Li Y., Vandenboom T.G., Wang Z., Kong D., Ali S., Philip P.A., Sarkar F.H. miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res. 2010, 70:1486-1495.
79. Liedtke C., Mazouni C., Hess K.R., Andre F., Tordai A., Mejia J.A., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 2008, 26:1275-1281.
80. Lin Y., Bai L., Chen W., Xu S. The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin. Ther. Targets 2010, 14:45-55.
81. Liu B., Qu L., Tao H. Cyclo-oxygenase 2 up-regulates the effect of multidrug resistance. Cell Biol. Int. 2010, 34:21-25.
82. Liu G., Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I.R., Lu L., Irvin D., Black K.L., Yu J.S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 2006, 5:1-12.
83. Liu T., Cheng W., Lai D., Huang Y., Guo L. Characterization of primary ovarian cancer cells in different culture systems. Oncol. Rep. 2010, 23:1277-1284.
84. Liu T., Xu F., Du X., Lai D., Liu T., Zhao Y., Huang Q., Jiang L., Huang W., Cheng W., Liu Z. Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1. Mol. Cell Biochem. 2010, 340:265-273.
85. Lopez-Chavez A., Carter C.A., Giaccone G. The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer. Curr. Opin. Investig. Drugs 2009, 10:1305-1314.
86. LoPiccolo J., Blumenthal G.M., Bernstein W.B., Dennis P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat. 2008, 11:32-50.
87. Ma L., Teruya-Feldstein J., Weinberg R.A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449:682-688.
88. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
89. Mehta K., Osipo C. Trastuzumab resistance: role for Notch signaling. Sci. World J. 2009, 9:1438-1448.
90. Meister G., Landthaler M., Dorsett Y., Tuschl T. Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA 2004, 10:544-550.
91. Melkamu T., Zhang X., Tan J., Zeng Y., Kassie F. Alteration of microRNA expression in vinyl carbamate-induced mouse lung tumors and modulation by the chemopreventive agent indole-3-carbinol. Carcinogenesis 2010, 31:252-258.
92. Miller T.E., Ghoshal K., Ramaswamy B., Roy S., Datta J., Shapiro C.L., Jacob S., Majumder S. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J. Biol. Chem. 2008, 283:29897-29903.
93. Morel A.P., Lievre M., Thomas C., Hinkal G., Ansieau S., Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008, 3:e2888.
94. Nasser M.W., Datta J., Nuovo G., Kutay H., Motiwala T., Majumder S., Wang B., Suster S., Jacob S.T., Ghoshal K. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J. Biol. Chem. 2008, 283:33394-33405.
95. Ong C.W., Kim L.G., Kong H.H., Low L.Y., Iacopetta B., Soong R., Salto-Tellez M. CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod. Pathol. 2010, 23:450-457.
96. Orom U.A., Kauppinen S., Lund A.H. LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene 2006, 372:137-141.
97. Orom U.A., Lund A.H. Isolation of microRNA targets using biotinylated synthetic microRNAs. Methods 2007, 43:162-165.
98. Paik S., Tang G., Shak S., Kim C., Baker J., Kim W., Cronin M., Baehner F.L., Watson D., Bryant J., Costantino J.P., Geyer C.E., Wickerham D.L., Wolmark N. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 2006, 24:3726-3734.
99. Park S.M., Gaur A.B., Lengyel E., Peter M.E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008, 22:894-907.
100. Patrawala L., Calhoun T., Schneider-Broussard R., Zhou J., Claypool K., Tang D.G. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and A. Cancer Res. 2005, 65:6207-6219.
101. Radisky D.C., LaBarge M.A. Epithelial-mesenchymal transition and the stem cell phenotype. Cell Stem Cell 2008, 2:511-512.
102. Rausch V., Liu L., Kallifaditis G., Baumann B., Mattern J., Gladkich J., et al. Synergistic activity of sorafenib and sulphorane abolishes pancreatic cancer stem cell characteristics. Cancer Res. 2010, 70:5004-5013.
103. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
104. Rho J.K., Choi Y.J., Lee J.K., Ryoo B.Y., Na I.I., Yang S.H., Kim C.H., Lee J.C. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 2009, 63:219-226.
105. Riccioni R., Dupuis M.L., Bernabei M., Petrucci E., Pasquini L., Mariani G., Cianfriglia M., Testa U. The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells Mol. Dis. 2010, 45:86-92.
106. Rui W., Bing F., Hai-Zhu S., Wei D., Long-Bang C. Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1). J. Cell Mol. Med. 2010, 14:206-214.
107. Sabbah M., Emami S., Redeuilh G., Julien S., Prevost G., Zimber A., Ouelaa R., Bracke M., De W.O., Gespach C. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist. Updat. 2008, 11:123-151.
108. Saito Y., Uchida N., Tanaka S., Suzuki N., Tomizawa-Murasawa M., Sone A., Najima Y., Takagi S., Aoki Y., Wake A., Taniguchi S., Shultz L.D., Ishikawa F. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat. Biotechnol. 2010, 28:275-280.
109. Sarkar F.H., Li Y., Wang Z., Kong D., Ali S. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist. Updat. 2010, 13:57-66.
110. Shafee N., Smith C.R., Wei S., Kim Y., Mills G.B., Hortobagyi G.N., Stanbridge E.J., Lee E.Y. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res. 2008, 68:3243-3250.
111. Shah A.N., Summy J.M., Zhang J., Park S.I., Parikh N.U., Gallick G.E. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann. Surg. Oncol. 2007, 14:3629-3637.
112. Shi L., Zhang J., Pan T., Zhou J., Gong W., Liu N., Fu Z., You Y. MiR-125b is critical for the suppression of human U251 glioma stem cell proliferation. Brain Res. 2010, 1312:120-126.
113. Shi M.F., Jiao J., Lu W.G., Ye F., Ma D., Dong Q.G., Xie X. Identification of cancer stem cell-like cells from human epithelial ovarian carcinoma cell line. Cell Mol. Life Sci. 2010.
114. Shimono Y., Zabala M., Cho R.W., Lobo N., Dalerba P., Qian D., et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009, 138:592-603.
115. Singh A., Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 10.1038/onc.2010.215.
116. Sokol J.P., Neil J.R., Schiemann B.J., Schiemann W.P. The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-β. Breast Cancer Res. 2005, 7:R844-R853.
117. Song B., Wang Y., Titmus M.A., Botchkina G., Formentini A., Kornmann M., Ju J. Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol. Cancer 2010, 9:1-10.
118. Song B., Wang Y., Xi Y., Kudo K., Bruheim S., Botchkina G.I., Gavin E., Wan Y., Formentini A., Kornmann M., Fodstad O., Ju J. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009, 28:4065-4074.
119. Styczynski J., Drewa T. Leukemic stem cells: from metabolic pathways and signaling to a new concept of drug resistance targeting. Acta Biochim. Pol. 2007, 54:717-726.
120. Sun M., Estrov Z., Ji Y., Coombes K.R., Harris D.H., Kurzrock R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol. Cancer Ther. 2008, 7:464-473.
121. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5:219-234.
122. Tang C., Ang B.T., Pervaiz S. Cancer stem cell: target for anti-cancer therapy. FASEB J. 2007, 21:3777-3785.
123. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
124. Thiery J.P., Sleeman J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 2006, 7:131-142.
125. Thomson S., Buck E., Petti F., Griffin G., Brown E., Ramnarine N., Iwata K.K., Gibson N., Haley J.D. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 2005, 65:9455-9462.
126. To K., Fotovati A., Reipas K.M., Law J.H., Hu K., Wang J., et al. Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res. 2010, 70:2840-2851.
127. Todaro M., Alea M.P., Di Stefano A.B., Cammareri P., Vermeulen L., Iovino F., Tripodo C., Russo A., Gulotta G., Medema J.P., Stassi G. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007, 1:389-402.
128. Tokar E.J., Qu W., Liu J., Liu W., Webber M.M., Phang J.M., Waalkes M.P. Arsenic-specific stem cell selection during malignant transformation. J. Natl. Cancer Inst. 2010, 102:638-649.
129. Toole B.P., Slomiany M.G. Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance. Drug Resist. Updat. 2008, 11:110-121.
130. Tsang W.P., Kwok T.T. Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. J. Nutr. Biochem. 2010, 21:140-146.
131. Vazquez-Martin A., Oliveras-Ferraros C., Barco S.D., Martin-Castillo B., Menendez J.A. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res. Treat. 2010, 10.1007/s10549-010-0924-x.
132. Vere White R.W., Vinall R.L., Tepper C.G., Shi X.B. MicroRNAs and their potential for translation in prostate cancer. Urol. Oncol. 2009, 27:307-311.
133. Vetter G., Saumet A., Moes M., Vallar L., Le B.A., Laurini C., Sabbah M., Arar K., Theillet C., Lecellier C.H., Friederich E. miR-661 expression in SNAI1-induced epithelial to mesenchymal transition contributes to breast cancer cell invasion by targeting Nectin-1 and StarD10 messengers. Oncogene 2010, 10.1038/onc.2010.181.
134. Voulgari A., Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim. Biophys. Acta 2009, 1796:75-90.
135. Wang B., Hsu S.H., Majumder S., Kutay H., Huang W., Jacob S.T., Ghoshal K. TGFβ-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 2010, 29:1787-1797.
136. Wang B., Yang H., Huang Y.Z., Yan R.H., Liu F.J., Zhang J.N. Biologic characteristics of the side population of human small cell lung cancer cell line H446. Chin. J. Cancer 2010, 29:254-260.
137. Wang Z., Ahmad A., Li Y., Kong D., Azmi A.S., Banerjee S., Sarkar F.H. Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim. Biophys. Acta 2010, 1806:122-130.
138. Wang Z., Kong D., Li Y., Sarkar F.H. PDGF-D signaling: a novel target in cancer therapy. Curr. Drug Targets 2009, 10:38-41.
139. Wang Z., Li Y., Banerjee S., Sarkar F.H. Exploitation of the Notch signaling pathway as a novel target for cancer therapy. Anticancer Res. 2008, 28:3621-3630.
140. Wang Z., Li Y., Banerjee S., Sarkar F.H. Emerging role of Notch in stem cells and cancer. Cancer Lett. 2009, 279:8-12.
141. Wang Z., Li Y., Kong D., Ahmad A., Banerjee S., Sarkar F.H. Cross-talk between miRNA and Notch signaling pathways in tumor development and progression. Cancer Lett. 2010, 292:141-148.
142. Wang Z., Li Y., Kong D., Banerjee S., Ahmad A., Azmi A.S., Ali S., Abbruzzese J.L., Gallick G.E., Sarkar F.H. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009, 69:2400-2407.
143. Wellner U., Schubert J., Burk U.C., Schmalhofer O., Zhu F., Sonntag A., et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 2009, 11:1487-1495.
144. Wong P., Iwasaki M., Somervaille T.C., Ficara F., Carico C., Arnold C., Chen C.Z., Cleary M.L. The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. Cancer Res. 2010, 70:3833-3842.
145. Wright M.H., Robles A.I., Herschkowitz J.I., Hollingshead M.G., Anver M.R., Perou C.M., Varticovski L. Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1. Mol. Cancer 2008, 7:1-12.
146. Xia L., Zhang D., Du R., Pan Y., Zhao L., Sun S., Hong L., Liu J., Fan D. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int. J. Cancer 2008, 123:372-379.
147. Yang A.D., Fan F., Camp E.R., van B.G., Liu W., Somcio R., Gray M.J., Cheng H., Hoff P.M., Ellis L.M. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin. Cancer Res. 2006, 12:4147-4153.
148. Yang H., Kong W., He L., Zhao J.J., O'Donnell J.D., Wang J., Wenham R.M., Coppola D., Kruk P.A., Nicosia S.V., Cheng J.Q. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008, 68:425-433.
149. Yauch R.L., Januario T., Eberhard D.A., Cavet G., Zhu W., Fu L., Pham T.Q., Soriano R., Stinson J., Seshagiri S., Modrusan Z., Lin C.Y., O'Neill V., Amler L.C. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin. Cancer Res. 2005, 11:8686-8698.
150. Yu F., Deng H., Yao H., Liu Q., Su F., Song E. Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene 2010, 10.1038/onc.2010.167.
151. Zhang N., Li R., Tao K.S., Cao D.Y., Ti Z.Y., Ding R., Cai L., Zhang F.Q., Dou K.F. Characterization of a stem-like population in hepatocellular carcinoma MHCC97 cells. Oncol. Rep. 2010, 23:827-831.
152. Zhao J.J., Lin J., Yang H., Kong W., He L., Ma X., Coppola D., Cheng J.Q. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J. Biol. Chem. 2008, 283:31079-31086.
153. Zhou S., Schuetz J.D., Bunting K.D., Colapietro A.M., Sampath J., Morris J.J., Lagutina I., Grosveld G.C., Osawa M., Nakauchi H., Sorrentino B.P. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 2001, 7:1028-1034.
154. Zhu H., Wu H., Liu X., Evans B.R., Medina D.J., Liu C.G., Yang J.M. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem. Pharmacol. 2008, 76:582-588.